These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

967 related items for PubMed ID: 8689882

  • 41. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
    Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ.
    J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
    [Abstract] [Full Text] [Related]

  • 42. SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive.
    Negri P, Agnello G, Borghesani F, Tomain L, Minisci N, D'Errico G, Cavallini AR.
    Acta Eur Fertil; 1987 Nov; 18(6):375-80. PubMed ID: 3454501
    [Abstract] [Full Text] [Related]

  • 43. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B.
    Ann Pharmacother; 1995 Nov; 29(7-8):736-42. PubMed ID: 8520092
    [Abstract] [Full Text] [Related]

  • 44. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP.
    Lancet; 1995 Dec 16; 346(8990):1593-6. PubMed ID: 7500751
    [Abstract] [Full Text] [Related]

  • 45. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K, Rolland R, Brosens I, Moorrees M, Deprest J, Tuominen J, Lähteenmäki P.
    Am J Obstet Gynecol; 1998 Jul 16; 179(1):41-6. PubMed ID: 9704763
    [Abstract] [Full Text] [Related]

  • 46. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W, Staks T, Jütting G.
    Contraception; 1994 Dec 16; 50(6):563-79. PubMed ID: 7705098
    [Abstract] [Full Text] [Related]

  • 47. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R.
    J Clin Endocrinol Metab; 1995 Jun 16; 80(6):1816-21. PubMed ID: 7775629
    [Abstract] [Full Text] [Related]

  • 48. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C, Fitzner M, Kuhl H.
    Horm Res; 1991 Jun 16; 36(5-6):238-46. PubMed ID: 1823082
    [Abstract] [Full Text] [Related]

  • 49. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J, Müller U, Düsterberg B.
    Contraception; 1997 Mar 16; 55(3):131-7. PubMed ID: 9115000
    [Abstract] [Full Text] [Related]

  • 50. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
    Winkler UH, Schindler AE, Endrikat J, Düsterberg B.
    Contraception; 1996 Feb 16; 53(2):75-84. PubMed ID: 8838483
    [Abstract] [Full Text] [Related]

  • 51. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive.
    Cachrimanidou AC, Hellberg D, Nilsson S, von Schoulz B, Crona N, Siegbahn A.
    Contraception; 1994 Aug 16; 50(2):153-65. PubMed ID: 7956214
    [Abstract] [Full Text] [Related]

  • 52. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
    Siegberg R, Nilsson CG, Stenman UH, Widholm O.
    Fertil Steril; 1984 Jun 16; 41(6):888-93. PubMed ID: 6233177
    [Abstract] [Full Text] [Related]

  • 53. Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
    Crona N, Silfverstolpe G, Samsioe G.
    Contraception; 1984 Mar 16; 29(3):261-70. PubMed ID: 6234148
    [Abstract] [Full Text] [Related]

  • 54. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
    Paoletti AM, Orrù M, Floris S, Mannias M, Vacca AM, Ajossa S, Guerriero S, Melis GB.
    Contraception; 2000 Apr 16; 61(4):259-63. PubMed ID: 10899481
    [Abstract] [Full Text] [Related]

  • 55. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives.
    Hümpel M, Täuber U, Kuhnz W, Pfeffer M, Brill K, Heithecker R, Louton T, Steinberg B, Seifert W, Schütt B.
    Am J Obstet Gynecol; 1990 Jul 16; 163(1 Pt 2):329-33. PubMed ID: 2142574
    [Abstract] [Full Text] [Related]

  • 56. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
    Suikkari AM, Tiitinen A, Stenman UH, Seppälä M, Laatikainen T.
    Fertil Steril; 1991 May 16; 55(5):895-9. PubMed ID: 1708731
    [Abstract] [Full Text] [Related]

  • 57. The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate.
    Klove KL, Roy S, Lobo RA.
    Contraception; 1984 Apr 16; 29(4):319-24. PubMed ID: 6235099
    [Abstract] [Full Text] [Related]

  • 58. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS, Chapdelaine A, Upmalis D, Olson W, Smith J.
    Acta Obstet Gynecol Scand Suppl; 1992 Apr 16; 156():9-14. PubMed ID: 1324557
    [Abstract] [Full Text] [Related]

  • 59. Long-term profile of a new progestin.
    Lippman J.
    Int J Fertil; 1992 Apr 16; 37 Suppl 4():218-22. PubMed ID: 1362189
    [Abstract] [Full Text] [Related]

  • 60. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W.
    Thromb Haemost; 1996 Nov 16; 76(5):729-34. PubMed ID: 8950781
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.